183 related articles for article (PubMed ID: 22252660)
1. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
Shah NP
Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
[No Abstract] [Full Text] [Related]
2. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
Thomas X
Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
4. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Nickel RS; Daves M; Keller F
Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
[No Abstract] [Full Text] [Related]
5. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
6. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
7. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.
Jain P; Romo CG; Khoury HJ; Kantarjian H; Cortes J
Haematologica; 2013 Nov; 98(11):e141-2. PubMed ID: 24186316
[No Abstract] [Full Text] [Related]
8. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
9. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib for chronic myeloid leukemia.
Goldman JM
N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
[No Abstract] [Full Text] [Related]
13. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
16. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
[TBL] [Abstract][Full Text] [Related]
17. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
O'Hare T; Deininger MW; Eide CA; Clackson T; Druker BJ
Clin Cancer Res; 2011 Jan; 17(2):212-21. PubMed ID: 21098337
[TBL] [Abstract][Full Text] [Related]
18. Where exactly does ponatinib fit in chronic myelogenous leukemia?
Berman E
J Natl Compr Canc Netw; 2014 Nov; 12(11):1615-20. PubMed ID: 25361807
[TBL] [Abstract][Full Text] [Related]
19. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
Andrews C; Lipton J
Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
[No Abstract] [Full Text] [Related]
20. Success is built on failures: tackling the challenge of ponatinib failure.
Hiwase D; Ross D
Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
